Madrigal Pharmaceuticals Q2 2024 Earnings Report $308.44 +15.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Madrigal Pharmaceuticals EPS ResultsActual EPS-$7.10Consensus EPS -$7.55Beat/MissBeat by +$0.45One Year Ago EPS-$4.69Madrigal Pharmaceuticals Revenue ResultsActual Revenue$14.64 millionExpected Revenue$4.25 millionBeat/MissBeat by +$10.39 millionYoY Revenue Growth+146,280.00%Madrigal Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/7/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseMDGL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Your chance to get on the next “60-Second Trade” (Ad)Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Madrigal Pharmaceuticals Earnings HeadlinesMadrigal Pharmaceuticals' SWOT analysis: rezdiffra launch key to stock's futureDecember 19 at 8:29 PM | uk.investing.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $347.33 Average Price Target from AnalystsDecember 16, 2024 | americanbankingnews.comYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!December 21, 2024 | WealthPress (Ad)Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.com3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise MoveNovember 23, 2024 | fool.comMadrigal Pharmaceuticals price target raised to $400 from $350 at OppenheimerNovember 21, 2024 | markets.businessinsider.comSee More Madrigal Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email. Email Address About Madrigal PharmaceuticalsMadrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.View Madrigal Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
